natgillin/translations-raw huggingface dataset:
The incidence rates (95% CI) for serious infections was 3.0 (2.3, 3.8) per 100 patient-years for abatacept-treated patients and 2.3 (1.5, 3.3) per 100 patient-years for placebo-treated patients in the double-blind studies. 
Stopa incidencije (95% CI) ozbiljnih infekcija u dvostruko slijepim ispitivanjima iznosila je 3,0 (2,3; 3,8) na 100 bolesnik-godina u bolesnika liječenih abataceptom te 2,3 (1,5; 3,3) na 100 bolesnik-godina u bolesnika koji su primali placebo.
− If you develop symptoms suggestive of infections, such as fever, persistent cough, weight loss, or listlessness, seek medical attention immediately. 
Ako dobijete simptome koji upućuju na infekcije, kao što su vrućica, uporan kašalj, gubitak tjelesne težine ili bezvoljnost, odmah potražite liječničku pomoć.
Uncommon Palpitations, tachycardia, bradycardia 
Srčani poremećaji manje često palpitacije, tahikardija, bradikardija
12% 14%*** 2% NAd 
12% 14%*** 2% NDd
To minimise foam formation in solutions of ORENCIA the vial should be rotated with gentle swirling until the contents are completely dissolved. 
Kako biste smanjili pjenjenje otopine lijeka ORENCIA, bočicu treba nježno okretati dok se sadržaj potpuno ne otopi.
PHARMACEUTICAL FORM AND CONTENTS Solution for injection in pre-filled syringe 
4. FARMACEUTSKI OBLIK I SADRŽAJ Otopina za injekciju u napunjenoj štrcaljki
Needle Cover (ORANGE Cap) 
Pokrov igle (NARANČASTI zatvarač)
- Do not store any unused portion of the infusion solution for reuse. 
- Neiskorišteni dio otopine za infuziju ne smije se čuvati za ponovnu primjenu.
In PsA-I, patients were randomised to receive intravenous placebo or abatacept 3 mg/kg (3/3 mg/kg), 10 mg/kg (10/10 mg/kg), or two doses of 30 mg/kg followed by 10 mg/kg (30/10 mg/kg), on day 1, 15, 29, and then every 28 days thereafter. 
PsA-I, bolesnici su bili randomizirani za intravensko primanje placeba ili abatacepta u dozi od 3 mg/kg (3/3 mg/kg), abatacepta u dozi od 10 mg/kg (10/10 mg/kg) ili dviju doza abatacepta od 30 mg/kg, a zatim doze od 10 mg/kg (30/10 mg/kg) 1., 15. i 29. dana te svakih 28 dana nakon toga.
No systemic accumulation of abatacept occurred upon continued repeated treatment with 10 mg/kg at monthly intervals in rheumatoid arthritis patients. 
U bolesnika s reumatoidnim artritisom nije došlo do sustavne akumulacije abatacepta nakon kontinuiranog ponovljenog liječenja dozom od 10 mg/kg u mjesečnim intervalima.
Immediately after reconstitution, the concentrate must be further diluted to 100 mL with sodium chloride 9 mg/mL (0.9%) solution for injection. 
Odmah nakon rekonstitucije, koncentrat se mora dodatno razrijediti do volumena od 100 ml otopinom natrijevog klorida za injekciju od 9 mg/ml (0,9%).
Abatacept in pJIA patients has also been studied with the subcutaneous formulation in children and adolescents with moderate to severe active pJIA, ages 2 to 17 years with an inadequate response or intolerance to at least one DMARD, which may have included biologic agents. 
U bolesnika s pJIA-om abatacept se također ispitivao u supkutanoj formulaciji u djece i adolescenata s umjerenim do teškim oblikom aktivnog pJIA-a u dobi od 2 do 17 godina koji na najmanje jedan DMARD nisu dovoljno dobro odgovorili ili ga nisu podnosili, a koji je mogao biti i biološki lijek.
Slowly add the reconstituted ORENCIA solution from each vial to the infusion bag or bottle using the same silicone-free disposable syringe provided with each vial. 
Polako dodajte pripremljenu otopinu lijeka ORENCIA iz svake bočice u infuzijsku vrećicu ili bocu, koristeći istu nesilikonsku štrcaljku za jednokratnu uporabu priloženu uz svaku bočicu.
87.5 mg/0.7 mL light blue plunger 
87,5 mg/0,7 mL svjetloplavi klip
Patients were randomised to receive placebo or abatacept 3 mg/kg, 10 mg/kg, or two doses of 30 mg/kg followed by 10 mg/kg, without escape for 24 weeks, followed by open label abatacept 10 mg/kg monthly intravenous every month. 
Bolesnici su bili randomizirani za primanje placeba, abatacepta u dozi od 3 mg/kg, abatacepta u dozi od 10 mg/kg ili dviju doza abatacepta od 30 mg/kg, praćenih s 10 mg/kg tijekom 24 tjedna, bez mogućnosti prijevremenog prelaska s placeba na abatacept (engl. escape), nakon čega je uslijedila otvorena primjena abatacepta u dozi od 10 mg/kg intravenski svaki mjesec.
Typical estimates for distribution volume and elimination half-life were 0.12 L/kg and 11.4 days, respectively, for a child weighing 40 kg. As a result of the higher body-weight normalised clearance and volume of distribution in pJIA patients, the predicted and observed systemic exposures of abatacept were lower than that observed in adults, such that the observed mean (range) peak and trough concentrations were 204 (66 to 595) mcg/mL and 10.6 (0.15 to 44.2) mcg/mL, respectively, in patients weighing less than 40 kg, and 229 (58 to 700) mcg/mL and 13.1 (0.34 to 44.6) mcg/mL, respectively, in patients weighing 40 kg or greater. 
Kao rezultat većeg klirensa normaliziranog za tjelesnu težinu i većeg volumena distribucije u bolesnika s pJIA-om, predviđene i opažene razine sistemske izloženosti abataceptu bile su niže nego u odraslih, tako da su opažene prosječne (raspon) najviše i najniže koncentracije bile 204 (66 do 595) µg/ml i 10,6 (0,15 do 44,2) µg/ml u bolesnika tjelesne težine manje od 40 kg, odnosno 229 (58 do 700) µg/ml i 13,1 (0,34 do 44,6) µg/ml u bolesnika tjelesne težine 40 kg ili više.
ORENCIA can be received with other medicines commonly used to treat rheumatoid arthritis, such as steroids or painkillers, including non-steroidal anti-inflammatories such as ibuprofen or diclofenac. 
ORENCIA se može primati s drugim lijekovima koji se uobičajeno koriste za liječenje reumatoidnog artritisa, kao što su steroidi ili lijekovi protiv bolova, uključujući nesteroidne protuupalne lijekove poput ibuprofena ili diklofenaka.
- To minimise foam formation in solutions of ORENCIA, the vial should be rotated with gentle swirling until the contents are completely dissolved. 
- - Kako biste smanjili stvaranje pjene u otopini lijeka ORENCIA, bočicu treba nježno okretati dok se sadržaj potpuno ne otopi.
If a single intravenous dose is given to start the treatment, the first subcutaneous injection of ORENCIA should be given within a day of the intravenous infusion, followed by the weekly 125 mg subcutaneous injections. 
Ako na početku liječenja primite jednu dozu lijeka u venu, prvu supkutanu (potkožnu) injekciju lijeka ORENCIA trebate primiti unutar jednoga dana nakon infuzije u venu, nakon čega će se liječenje nastaviti tjednim supkutanim (potkožnim) injekcijama u dozi od 125 mg.
In the cumulative period in clinical trials in 7,044 patients treated with abatacept during 20,510 patient-years, the incidence rate of serious infections was 2.4 per 100 patient-years, and the annualised incidence rate remained stable. 
U kumulativnom razdoblju u kliničkim ispitivanjima, u 7044 bolesnika liječena abataceptom tijekom 20 510 bolesnik-godina stopa incidencije ozbiljnih infekcija iznosila je 2,4 na 100 bolesnik-godina te je ostala stabilna na godišnjoj razini.
ORENCIA can be used with other medicines commonly used to treat rheumatoid arthritis, such as steroids or painkillers, including non-steroidal anti-inflammatories such as ibuprofen or diclofenac. 
ORENCIA se može primjenjivati s drugim lijekovima koji se uobičajeno koriste za liječenje reumatoidnog artritisa, kao što su steroidi ili lijekovi protiv bolova, uključujući nesteroidne protuupalne lijekove poput ibuprofena ili diklofenaka.
Of the 190 patients enrolled, 170 completed Period A, 65% (123/190) achieved an ACR Pedi 30 response, and 122 were randomised to Period B. Responses were similar in all subtypes of pJIA studied and for patients with or without methotrexate use. 
Od 190 bolesnika uključenih u ispitivanje, 170 ih je završilo Razdoblje A, 65% (123/190) njih je postiglo odgovor Ped ACR30, a 122 bolesnika randomizirana su u Razdoblje B.
50 mg/0.4 mL Pre-filled Syringe 
50 mg/0,4 mL Napunjena štrcaljka
They had active disease, with a mean active joint count of 11.8, mean number of joints with loss of motion of 10.3, and a mean elevated C-reactive protein (CRP) level of 1.24 mg/dL at baseline. 
Bolesnici su imali aktivnu bolest te su na početku ispitivanja imali prosječno 11,8 aktivnih zglobova, 10,3 zgloba u kojima je pokretljivost bila izgubljena i povišene razine C-reaktivnog proteina (CRP) (prosječna vrijednost: 1,24 mg/dl).
Abatacept has been studied in patients with active rheumatoid arthritis in placebo-controlled clinical trials (2,653 patients with abatacept, 1,485 with placebo). 
Abatacept je ispitivan u bolesnika s aktivnim reumatoidnim artritisom u placebom kontroliranim kliničkim ispitivanjima (2653 bolesnika primala su abatacept, a 1485 placebo).
Table 9: 
Tablica 9:
Please refer to the ORENCIA powder for concentrate for solution for infusion 250 mg and ORENCIA solution for injection in prefilled syringe 125 mg, 87.5 mg and 50 mg SmPCs. 
Vidjeti sažetak opisa svojstava lijeka za ORENCIA prašak za koncentrat za otopinu za infuziju od 250 mg i ORENCIA otopinu za injekciju u napunjenoj štrcaljki od 125 mg, 87,5 mg i 50 mg.
D. Gather your additional supplies and keep them within easy reach. 
Prikupite dodatni pribor i držite ga nadohvat ruke.
DO NOT remove the needle cover from the Pen while allowing it to reach room temperature. 
NEMOJTE skidati pokrov igle s brizgalice dok čekate da se ugrije na sobnu temperaturu.
Vial (15 mL Type 1 glass) with a stopper (halobutyl-rubber) and flip off seal (aluminium). 
Bočica (15 ml, staklo tipa 1) s čepom (halobutilna guma) i zaštitnom "flip-off" kapicom i prstenom (aluminij)
In study VI, which only included adults, a significantly higher proportion of patients in the abatacept plus methotrexate group (41%) achieved DAS28 (CRP)-defined remission (score < 2.6) versus the methotrexate plus placebo group (23%) at year 1. 
U ispitivanju VI, u koje su uključeni samo odrasli bolesnici, nakon godinu dana liječenja je remisiju prema indeksu DAS28--CRP (rezultat < 2,6) postigao značajno veći udio bolesnika u skupini abatacept i metotreksat (41%) u usporedbi s bolesnicima u skupini metotreksat i placebo (23%).
- Insert the syringe needle into the vial through the centre of the rubber stopper and direct the stream of water for injections to the glass wall of the vial. 
- - Uvedite iglu u bočicu kroz sredinu gumenog čepa i usmjerite mlaz vode za injekcije na staklenu stijenku bočice.
Gather supplies for your injection on a clean, flat surface (only the ClickJect Pre-filled Pen is included in the package): Alcohol swab 
Položite pribor za injekciju na čistu i ravnu površinu (u pakiranje je uključena samo napunjena brizgalica ClickJect): vatu natopljena alkoholom flaster pamučnu vatu ili gazu napunjenu brizgalicu ClickJect spremnik za odlaganje oštrih predmeta
• Please make sure you also have a list of all your other medicines with you at any visit to a health care professional. 
• Prilikom svakog posjeta liječniku obavezno ponesite popis svih drugih lijekova koje uzimate.
In SC-I, the ACR 20 response rates at day 169 for subcutaneous and intravenous abatacept were respectively 78.3% (472/603 SC) and 76.0% (456/600 IV) in patients < 65 years, versus 61.1% (55/90 SC) and 74.4% (58/78 IV) for patients ≥ 65 years. 
U ispitivanju SC-I udio odgovora ACR20 169. dana iznosio je 78,3% (472/603) kod supkutane primjene i 76,0% (456/600) kod intravenske primjene u bolesnika mlađih od 65 godina, u odnosu na 61,1% (55/909) kod supkutane primjene te 74,4% (58/78) kod intravenske primjene u bolesnika u dobi od ≥ 65 godina.
In placebo-controlled clinical trials, in comparison with patients treated with TNFinhibitors and placebo, patients who received combination TNF-inhibitors with abatacept experienced an increase in overall infections and serious infections (see section 4.5). 
U placebom kontroliranim kliničkim ispitivanjima je u bolesnika liječenih kombinacijom TNF-inhibitora i abatacepta zabilježen porast broja ukupnih infekcija i ozbiljnih infekcija u usporedbi s bolesnicima koji su primali TNF-inhibitore i placebo (vidjeti dio 4.5).
B. Position the syringe and inject ORENCIA Hold the syringe by its body in one hand between your thumb and index finger (Figure 5). 
Držite štrcaljku za tijelo štrcaljke između palca i kažiprsta jedne ruke (Slika 5).
In pre-clinical embryo-fetal development studies no undesirable effects were observed at doses up to 29-fold a human 10 mg/kg dose based on AUC. 
U pretkliničkim istraživanjima embrio-fetalnog razvoja nisu zabilježene nuspojave pri dozama koje su, na temelju AUC-a, bile do 29 puta veće od doze za ljude od 10 mg/kg.
The abatacept + MTX group had less progression in structural damage compared with MTX group as reflected by mean treatment difference of the abatacept + MTX group versus MTX group (Table 6). 
+ MTX zabilježena je manja progresija strukturnog oštećenja nego u skupini koja je primala samo MTX, što pokazuje srednja vrijednost razlike između liječenja abataceptom + MTX-om i liječenja samo MTX-om (Tablica 6).
Let your Pre-filled syringe warm up. 
Pričekajte da se napunjena štrcaljka ugrije.
• See the ORENCIA package leaflet for more information. 
• Za dodatne informacije pročitajte uputu o lijeku za lijek ORENCIA.
With your other hand, gently pinch the cleaned skin. 
Drugom rukom nježno uhvatite nabor očišćene kože.
ORENCIA is usually used in combination with methotrexate, although ORENCIA may also be used alone in case of intolerance to methotrexate or if treatment with methotrexate is inappropriate. 
ORENCIA se obično primjenjuje u kombinaciji s metotreksatom, ali može se koristiti i sama ako bolesnik ne podnosi metotreksat ili ako liječenje metotreksatom nije prikladno.
Injection Reactions in adult patients treated with subcutaneous abatacept 
Reakcije na injekcije u odraslih bolesnika liječenih abataceptom primijenjenim supkutano
After removing the pre-filled syringe from the refrigerator the pre-filled syringe should be allowed to reach room temperature by waiting 30 minutes, before injecting ORENCIA. 
Nakon što se napunjena brizgalica izvadi iz hladnjaka, treba pričekati 30 minuta da se napunjena brizgalica zagrije na sobnu temperaturu prije injiciranja lijeka ORENCIA.
125 mg/mL orange plunger 
125 mg/mL narančasti klip
One patient was diagnosed with multiple sclerosis while in the extension period of the pJIA IV study. 
U jednog je bolesnika tijekom razdoblja nastavka ispitivanja pJIA IV dijagnosticirana multipla skleroza.
Placebo +DMARDsb n = 133 
Placebo +DMARD-i b n = 133
Choose your injection site in either the abdomen or front of the thigh. 
Odaberite mjesto injekcije na trbuhu ili prednjem dijelu bedara.
Do not use this medicine if the liquid is cloudy or discoloured, or has large particles. 
Ovaj lijek se ne smije upotrijebiti ako je tekućina mutna ili je promijenila boju, ili sadrži velike čestice.
Abatacept has been studied in patients with pJIA in 2 clinical trials (ongoing pJIA SC study and pJIA IV study). 
Abatacept se ispitivao u bolesnika s pJIA-om u dvama kliničkim ispitivanjima (ispitivanje pJIA SC, koje je u tijeku, i ispitivanje pJIA IV).
Population pharmacokinetic analyses revealed that there was a trend toward higher clearance of abatacept with increasing body weight. 
Analize populacijske farmakokinetike otkrile su trend povećanja klirensa abatacepta s povećanjem tjelesne težine.
A randomised, single(investigator)-blinded, non-inferiority study was conducted to assess the safety and efficacy of weekly subcutaneous (SC) abatacept without an abatacept intravenous (IV) loading dose versus every-other-weekly subcutaneous adalimumab, both with background MTX, in patients with an inadequate response to methotrexate (study SC-II). 
Randomizirano, jednostruko (za ispitivača) slijepo ispitivanje neinferiornosti provedeno je s ciljem ocjenjivanja sigurnosti i djelotvornosti abatacepta primijenjenog supkutano (s.c.) jedanput na tjedan bez intravenske (i.v.) udarne doze abatacepta naspram adalimumaba primijenjenog supkutano jedanput svaka dva tjedna u bolesnika koji nisu dovoljno dobro odgovorili na metotreksat; oba lijeka primjenjivala su se uz osnovnu terapiju MTX-om (ispitivanje SC-II).
Among the patients who entered the open-label 12 month period, 59% (125/213) of patients receiving continuous abatacept plus methotrexate treatment and 48% (92/192) of patients who initially received methotrexate and switched to combination with abatacept had no progression. 
Među bolesnicima koji su ušli u otvoreno 12-mjesečno razdoblje ispitivanja, progresija nije nastupila u 59% (125/213) onih koji su kontinuirano liječeni abataceptom i metotreksatom te u 48% (92/192) bolesnika koji su najprije primali metotreksat i placebo pa su potom prebačeni na kombinaciju s abataceptom.
ORENCIA solution for injection in pre-filled pen has not been studied in children and adolescents under the age of 18 years. 
ORENCIA otopina za injekciju u napunjenoj brizgalici nije ispitivana u djece i adolescenata mlađih od 18 godina.
DAS28-CRP Remissione 
Remisija prema indeksu DAS28-CR
Dispose of used ClickJect Pre-filled Pen into sharps disposal container right away after use. 
Upotrijebljenu napunjenu brizgalicu ClickJect odložite u spremnik za odlaganje oštrih predmeta odmah nakon uporabe.
In addition, study V investigated the safety and efficacy of abatacept or infliximab relative to placebo. 
V ispitivale su se sigurnost i djelotvornost abatacepta ili infliksimaba u odnosu na placebo.
Common (may affect up to 1 in 10 people): upper airway infection (including infections of nose, sinus and throat) fever 
Često (mogu se javiti u do 1 na 10 osoba): infekcija gornjih dišnih putova (uključujući infekcije nosa, sinusa i grla) vrućica
PREPARE YOUR CLICKJECT PEN 
Upoznajte svoju napunjenu brizgalicu ClickJect
Of the 133 (70%) patients with no prior TNF-inhibitor therapy, 101 (76%) achieved at least an ACR Pedi 30 response; of the 57 patients who had received prior TNF-inhibitor therapy, 22 (39%) achieved at least an ACR Pedi 30 response. 
Od 133 (70%) bolesnika koji prethodno nisu bili na terapiji TNF-inhibitorima, 101 (76%) je postigao barem odgovor Ped ACR30.
ORENCIA solution for injection is injected under the skin (subcutaneous use). 
ORENCIA otopina za injekciju injicira se supkutano (potkožno).
Dispose the used pre-filled syringe into sharps disposal container right away after use. 
Upotrijebljenu štrcaljku odložite u spremnik za odlaganje oštrih predmeta odmah nakon uporabe.
Immunogenicity in patients with pJIA treated with subcutaneous abatacept 
Imunogenost u bolesnika s pJIA-om liječenih supkutanom formulacijom abatacepta
Before you are given ORENCIA, your doctor may examine you for hepatitis. 
Prije nego što primite lijek ORENCIA, liječnik će Vas možda testirati na hepatitis.
This medicinal product contains 0.014 mmol sodium (0.322 mg) per pre-filled pen, that is to say essentially ‘sodium- free'. 
Ovaj lijek sadrži 0,014 (0,322 mg) mmol natrija po napunjenoj brizgalici, tj.zanemarive količine natrija.
EU/1/07/389/007 1 pre-filled syringe with needle guard EU/1/07/389/008 4 pre-filled syringes with needle guard EU/1/07/389/010 3 pre-filled syringes with needle guard 
EU/1/07/389/007 1 napunjene štrcaljke sa štitnikom za iglu EU/1/07/389/008 4 napunjene štrcaljke sa štitnikom za iglu EU/1/07/389/010 3 napunjene štrcaljke sa štitnikom za iglu
Concomitant medication, such as methotrexate, corticosteroids, and NSAIDs, did not influence abatacept apparent clearance. 
Istodobno primijenjeni lijekovi, kao što su metotreksat, kortikosteroidi i NSAIL-i, nisu utjecali na prividni klirens abatacepta.
Study I patients were randomised to receive abatacept 2 or 10 mg/kg or placebo for 12 months. 
I bolesnici su randomizirani da tijekom 12 mjeseci primaju abatacept u dozi od 2 ili 10 mg/kg, odnosno placebo.
- Upon complete dissolution of the powder, the vial should be vented with a needle to dissipate any foam that may be present. 
- - Nakon potpunog otapanja praška, bočicu treba odzračiti iglom kako bi se odstranila eventualna pjena.
Sharps containers are special puncture-resistant disposal bins that can be bought at many retail outlets. 
To je posebna posuda koja se ne može probušiti i može se kupiti u mnogim trgovinama.
Non-responder in Period A 
Nisu odgovorili u Razdoblju
In placebo-controlled clinical trials with abatacept, adverse reactions (ARs) were reported in 49.4% of abatacept-treated patients and 45.8% of placebo-treated patients. 
U placebom kontroliranim kliničkim ispitivanjima abatacepta nuspojave su prijavljene u 49,4% bolesnika liječenih abataceptom i 45,8% bolesnika koji su primali placebo.
Don't use the syringe if it is dropped without the needle cover in place. 
Nemojte upotrijebiti štrcaljku ako je pala bez poklopca igle.
Boolean Clinical Remission Estimate of Difference (95% CI) vs. MTX 
Klinička remisija prema načelima Booleove algebre Procijenjena razlika (95% CI) u odnosu na MTX
C. Check the liquid in the syringe Hold the syringe by its body, with the covered needle pointing down. 
Provjerite tekućinu u štrcaljki Držite štrcaljku za tijelo štrcaljke, prekrivenom iglom okrenutom prema dolje.
If a patient misses an injection of abatacept and is within three days of the planned date, he/she should be instructed to take the missed dose immediately and remain on the original weekly schedule. 
Propusti li bolesnik injekciju abatacepta, a od planirane primjene nije prošlo više od 3 dana, treba mu/joj savjetovati da odmah primijeni propuštenu dozu te se dalje pridržava originalnog tjednog rasporeda doziranja.
During the 12-week pre-filled pen period of the substudy, there were no deaths or related SAEs. 
Tijekom 12-tjednog razdoblja podispitivanja u kojem se lijek primjenjivao napunjenom brizgalicom nije zabilježen nijedan smrtni slučaj niti ozbiljne nuspojave povezane s lijekom.
Complete ALL steps for full-dose delivery: 
Da biste primijenili cijelu dozu, prođite kroz SVE navedene korake:
ORENCIA 87.5 mg solution for injection in pre-filled syringe Each pre-filled syringe contains 87.5 mg of abatacept in 0.7 mL. 
ORENCIA 87,5 mg otopina za injekciju u napunjenoj štrcaljki Jedna napunjena štrcaljka sadrži 87,5 mg abatacepta u 0,7 ml.
The overall safety profile was comparable between studies PsA-I and PsA-II and consistent with the safety profile in rheumatoid arthritis (Table 1). 
PsA-I i PsA-II te je bio u skladu sa sigurnosnim profilom kod reumatoidnog artritisa (Tablica 1).
Not assessed a day 169 Last Observation Carried Forward (LOCF) for patients treated in Period C b As observed 
Nisu ocijenjeni a Za bolesnike liječene u Razdoblju C dalje su se prenosili rezultati zabilježeni 169. dana b Prema opaženome
During Period B, the time to disease flare for the patients randomised to placebo was significantly shorter than for those randomised to abatacept (primary endpoint, p=0.0002; log-rank test). 
Tijekom Razdoblja B, vrijeme do razbuktavanja bolesti u bolesnika randomiziranih za placebo bilo je značajno kraće nego u bolesnika randomiziranih za abatacept (primarna mjera ishoda, p = 0,0002; log-rang test).
ORENCIA contains sodium 
ORENCIA sadrži natrij
AFTER THE INJECTION 
SAMO kad injekciju daje
Similarly, the frequencies of serious infection and malignancy among subcutaneous abatacept-treated patients over age 65 were higher than among those under age 65. 
Slično tomu, učestalost ozbiljnih infekcija i zloćudnih bolesti kod supkutane primjene abatacepta bila je veća u bolesnika starijih od 65 godina, nego u onih mlađih od 65 godina.
Medicinal products that affect the immune system, including abatacept, may blunt the effectiveness of some immunisations (see section 4.5). 
Lijekovi koji djeluju na imunološki sustav, uključujući abatacept, mogu umanjiti učinkovitost nekih cijepljenja (vidjeti dio 4.5).
The abatacept + MTX group had less progression in structural damage compared with MTX group as reflected by mean treatment difference of the abatacept + MTX group versus MTX group (Table 5). 
+ MTX zabilježena je manja progresija strukturnog oštećenja nego u skupini koja je primala samo MTX, što pokazuje srednja vrijednost razlike između liječenja abataceptom + MTX-om i liječenja samo MTX-om (Tablica 5).
Table 7: 
Tablica 7: